Sauter, Jennifer L.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 1,641

Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing

Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 1,367

Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer

Hellmann, M. D., Nathanson, T., Rizvi, H., Creelan, B. C., Sanchez-Vega, F., Ahuja, A., Ni, A., Novik, J. B., Mangarin, L. M. B., Abu-Akeel, M., et al. (2018) · Cancer Cell

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 1,095

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

Adusumilli, P. S., Zauderer, M. G., Rivière, I., Solomon, S. B., Rusch, V. W., O'Cearbhaill, R. E., Zhu, A., Cheema, W., Chintala, N. K., Halton, E., et al. (2021) · Cancer Discovery

CAR-T cell therapy researchCancer Immunotherapy and Biomarkers

Cited by 605

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

Cottrell, T. R., Thompson, E. D., Forde, P. M., Stein, J. E., Duffield, A. S., Anagnostou, V., Rekhtman, N., Anders, R. A., Cuda, J. D., Illei, P. B., et al. (2018) · Annals of Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 592

Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer

Vanguri, R. S., Luo, J., Aukerman, A. T., Egger, J. V., Fong, C. J., Horvat, N., Pagano, A., Araujo-Filho, J. D. A. B., Geneslaw, L., Rizvi, H., et al. (2022) · Nature Cancer

Cancer Immunotherapy and BiomarkersRadiomics and Machine Learning in Medical Imaging

Cited by 395

Insights into pathogenesis of fatal COVID‐19 pneumonia from histopathology with immunohistochemical and viral RNA studies

Sauter, J. L., Baine, M. K., Butnor, K. J., Buonocore, D. J., Chang, J. C., Jungbluth, A. A., Szabolcs, M. J., Morjaria, S., Mount, S. L., Rekhtman, N., et al. (2020) · Histopathology

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 104

New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center

Galateau Salle, F., Le Stang, N., Nicholson, A. G., Pissaloux, D., Churg, A., Klebe, S., Roggli, V. L., Tazelaar, H. D., Vignaud, J. M., Attanoos, R., et al. (2018) · Journal of Thoracic Oncology

Occupational and environmental lung diseasesIntraperitoneal and Appendiceal Malignancies

Cited by 93

Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

Ligero, M., Serna, G., El Nahhas, O. S. M., Sansano, I., Mauchanski, S., Viaplana, C., Calderaro, J., Toledo, R. A., Dienstmann, R., Vanguri, R. S., et al. (2024) · Cancer Research Communications

AI in cancer detectionCancer Immunotherapy and Biomarkers

Cited by 22